搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
15 小时
on MSN
Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
1 天
Bristol Myers Beats $6.4 Billion Lawsuit Over Delayed Cancer Drug
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...
FiercePharma
9 小时
BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing
For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...
BioSpace
8 小时
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
4 天
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
1 天
on MSN
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb ...
5 天
on MSN
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in ...
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
4 天
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
4 天
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
BioWorld
1 天
Prime’s $3.61B Bristol Myers deal is year’s fourth largest
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
STAT
1 天
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...
4 天
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈